Page last updated: 2024-12-05

4-nitrobenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-nitrobenzoic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-nitrobenzoic acid : A nitrobenzoic acid having the nitro group at the 4-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6108
CHEMBL ID101263
CHEBI ID262350
SCHEMBL ID43476
SCHEMBL ID15630318
MeSH IDM0052637

Synonyms (86)

Synonym
4-nitro-benzoic acid
CHEMBL101263 ,
para-nitrobenzoic acid
AKOS015831344
62-23-7
nitrodracylic acid
4-nitrobenzoic acid
kyselina p-nitrobenzoova
nsc-7707
p-nitrobenzoic acid
nsc7707
wln: wnr dvq
4-nitrodracylic acid
1-carboxy-4-nitrobenzene
benzoic acid, 4-nitro-
benzoic acid, p-nitro-
ccris 1185
p-nitrobenzenecarboxylic acid
ai3-00149
einecs 200-526-2
hsdb 2140
kyselina p-nitrobenzoova [czech]
nsc 7707
inchi=1/c7h5no4/c9-7(10)5-1-3-6(4-2-5)8(11)12/h1-4h,(h,9,10
NCGC00091607-01
4-nitrobenzoic acid, 98%
NCGC00091607-02
4nb ,
AC-10993
AKOS000118872
4-nitrobenzenecarboxylic acid
smr001252222
MLS002454442
N0156
p-nitrodracylic acid
chebi:262350 ,
A8599
NCGC00091607-03
NCGC00091607-04
4-nitrobenzoicacid
C18625
HMS3041D05
tox21_300131
NCGC00253917-01
cas-62-23-7
dtxcid90966
dtxsid3020966 ,
tox21_201258
NCGC00258810-01
STL168880
p-carboxynitrobenzene
bdbm50405310
AE-562/40227261
ec 200-526-2
unii-g83nwr61ow
g83nwr61ow ,
FT-0619175
4-aminobenzoic acid impurity a [ep impurity]
4-nitrobenzoic acid [usp-rs]
BP-30196
SCHEMBL43476
AKOS024268501
p-nitro benzoic acid
4-nitro benzoic acid
p-nitro-benzoic acid
p-nitro-benzoicacid
W-105029
SCHEMBL15630318
STR01385
mfcd00007352
F2191-0089
4-nitrobenzoic acid, purum, >=98.0% (hplc)
4-nitrobenzoic acid, united states pharmacopeia (usp) reference standard
D70606
4-nitrobenzoic acid, puriss., 99%
4-nitrobenzoic acid, vetec(tm) reagent grade, 98%
Z57127484
4-nitrobenzoic-2,6-d2 acid
para nitrobenzoic acid
CS-W020075
Q2823227
AMY8937
SY002161
PB43175
PD033171
EN300-18011

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" 2 Reduction of 4-nitrobenzoic acid was significantly decreased by antibiotic pretreatment; the mean decrease in reduction was 81% for animals doses orally and 73% for intraperitoneally dosed marmosets."( Influence of the gut microflora on the metabolism of 4-nitrobenzoic acid in the marmoset.
James, SP; Kuzniar, EJ, 1981
)
0.86
" Statistics for dose-response trend tests are calculated within body weight strata and pooled to obtain an overall dose-response trend test."( Dose-response trend tests for tumorigenesis, adjusted for body weight.
Gaylor, DW; Kodell, RL, 1999
)
0.3
" Large MW power and GAC dosage were beneficial for a completed decomposition of CAP."( Treatment of chloramphenicol-contaminated soil by microwave radiation.
Chen, J; Lin, L; Lu, X; Wan, J; Wang, L; Yuan, S, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrobenzoic acidAny member of the class of benzoic acids with at least one nitro substituent attached to the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
progesterone receptorHomo sapiens (human)Potency7.67240.000417.946075.1148AID1346784
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency4.73940.001530.607315,848.9004AID1224841; AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency68.38040.000229.305416,493.5996AID1259383
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency22.38720.001024.504861.6448AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.66840.001019.414170.9645AID588537
thyroid stimulating hormone receptorHomo sapiens (human)Potency23.24740.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency0.48830.143427.612159.8106AID1159516
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency15.84890.010039.53711,122.0200AID588547
VprHuman immunodeficiency virus 1Potency12.58931.584919.626463.0957AID651644
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Guanine nucleotide-binding protein GHomo sapiens (human)Potency35.48131.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-carbonic anhydrase 1Mycobacterium tuberculosis H37RvKi4.83000.00483.38419.8400AID1803218
Carbonic anhydrase 2Mycobacterium tuberculosis H37RvKi4.83000.00902.20969.8400AID1803218
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
methylationThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic catabolic processThiopurine S-methyltransferaseHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingThiopurine S-methyltransferaseHomo sapiens (human)
thiopurine S-methyltransferase activityThiopurine S-methyltransferaseHomo sapiens (human)
S-adenosyl-L-methionine bindingThiopurine S-methyltransferaseHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cytosolThiopurine S-methyltransferaseHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID213093Inhibition of purified human kidney thiopurine methyltransferase (TPMT)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates.
AID226478Hammett constant was evaluated1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID631927Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously measured after 24 hrs2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID1605095Inhibition of N-terminal His6-sumo-tagged full length Staphylococcus aureus ClpP expressed in Escherichia coli BL2 (DE3) at 10 uM pre-incubated for 10 mins before Suc-LY-AMC addition and measured after 1 hr by fluorescence based assay relative to control2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers
AID29132pI50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID28731Partition coefficient (logD2.0)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1145605Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1145614Dissociation constant, pKa of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID28692Concentration of the drug in the kidney of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1145616Increase in membrane potential in mollusc neurons assessed as conductance of potassium at pH 7.8 relative to salicylic acid1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID631930Dissociation constant, pKa of the compound2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID1145615Dissociation constant, pKa of the compound at pH 7.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID28691log LD50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID28693Concentration of the drug in the liver of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID226477Hammett constant was determined1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID1803218CA Inhibition Assay from Article 10.3109/14756366.2011.650168: \\Inhibition of the u00DF-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids.\\2013Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 28, Issue:2
Inhibition of the β-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (22.35)18.7374
1990's17 (20.00)18.2507
2000's11 (12.94)29.6817
2010's33 (38.82)24.3611
2020's5 (5.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.76 (24.57)
Research Supply Index4.55 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index89.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other93 (98.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]